Reproductive Medicine Associates (RMA), a leading provider in reproductive services and a pioneer in IVF research, proudly celebrated its 25th anniversary this month. Over the past quarter-century, RMA has made significant contributions to fertility preservation and infertility treatments, driving innovations such as single embryo transfer, egg freezing, and PGT-A testing, as well as advancing care for the LGBTQ+ community. Since its founding in 1999, this nationwide fertility network has achieved remarkable outcomes, resulting in over 50,000 healthy births in New Jersey alone, and has set new industry standards that have redefined the practice of fertility medicine.
Founded by Drs. Paul Bergh, Richard Scott, and Michael Drews, Reproductive Medicine Associates (RMA) opened its first clinic in Morristown, New Jersey, and has since expanded its network across the U.S., with locations in California, Colorado, Florida, New Jersey, Pennsylvania, Texas, and Washington.
“We are proud to celebrate our 25th anniversary, reflecting on RMA’s significant achievements in helping patients achieve their family dreams through evidence-based care,” said Lynn Mason, CEO of IVI RMA North America. “As we shape the future of fertility medicine, we remain dedicated to advancing reproductive care for the roughly 1 in 6 Americans facing infertility.”
Throughout its growth, RMA has prioritized research and scientific excellence. In 2017, RMA merged with Instituto Valenciano de Infertilidad (IVI), creating IVI-RMA Global, the largest assisted reproduction group globally, with over 190 clinics and 95 labs across 15 countries. In 2023, IVI RMA acquired Boston IVF and TRIO in Toronto, adding 13 labs and 32 offices in the U.S. and Canada to enhance its North American leadership.
“The field of reproductive endocrinology is just 50 years old, and for half of that time, RMA has led the way in setting new standards of care,” said Dr. Thomas Molinaro, Chief Medical Officer of IVI RMA North America.
RMA, alongside IVI RMA Global, has consistently focused on research, investing millions in improving IVF science and publishing over 1,000 research papers, including numerous clinical trials. This commitment has facilitated more than 300,000 births worldwide, establishing RMA as a leader in pioneering advancements like single embryo transfers, which significantly reduce multiple births and associated risks.
“The next 25 years will bring many changes, but our commitment to putting patients first and utilizing the best science to help them achieve their family goals will remain unchanged,” added Dr. Molinaro.
About RMA
Reproductive Medicine Associates (RMA) has been dedicated to building families through advanced treatment options and patient-centered care for 25 years. A leader in IVF research, RMA pioneered Single Embryo Transfer (SET) and Pre-Implantation Genetic Testing (PGT-A), enhancing outcomes and safety for mothers and babies alike. With practices nationwide, RMA has welcomed over 50,000 babies into loving families.
